Clinical Trial Update: Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study comparing D-RVd (daratumumab–lenalidomide–bortezomib–dexamethasone) versus RVd (lenalidomide–bortezomib–dexamethasone) in newly diagnosed multiple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-02-07